Published in Cancer Res on February 15, 1999
Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol (2001) 4.18
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol (2000) 1.82
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol (2001) 1.40
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res (2008) 1.32
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol (2001) 1.28
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res (2009) 1.22
Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol (2001) 1.21
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer (2012) 1.13
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer (2007) 1.09
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer (2004) 1.07
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer (2005) 1.05
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
A next-generation tissue microarray (ngTMA) protocol for biomarker studies. J Vis Exp (2014) 1.00
Helicobacter pylori infection induced alteration of gene expression in human gastric cells. Gut (2001) 0.99
Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol (2007) 0.99
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
Prostate cancer-from steroid transformations to clinical translation. Nat Rev Urol (2012) 0.93
Biomarker identification for prostate cancer and lymph node metastasis from microarray data and protein interaction network using gene prioritization method. ScientificWorldJournal (2012) 0.93
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci U S A (2009) 0.93
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol (2014) 0.92
Automated acquisition of stained tissue microarrays for high-throughput evaluation of molecular targets. J Mol Diagn (2003) 0.92
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep (2015) 0.91
Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol (2010) 0.91
Human RecQL4 helicase plays critical roles in prostate carcinogenesis. Cancer Res (2010) 0.91
Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol (2010) 0.91
Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers. Oncogenesis (2014) 0.91
Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia (2003) 0.90
Progress in the application of DNA microarrays. Environ Health Perspect (2001) 0.90
Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget (2015) 0.90
Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci (2013) 0.89
Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol (2002) 0.89
Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer (2015) 0.89
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Androgen receptor mutations and polymorphisms in African American prostate cancer. Int J Biol Sci (2014) 0.87
A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One (2013) 0.86
Expression and amplification of therapeutic target genes in retinoblastoma. Graefes Arch Clin Exp Ophthalmol (2004) 0.85
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med (2009) 0.85
Molecular staging of prostate cancer in the year 2007. World J Urol (2007) 0.85
Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch (2003) 0.84
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol (2013) 0.84
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids (2015) 0.84
[Mixed epithelial and stromal tumor of the kidney]. Pathologe (2004) 0.83
The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells. Cancers (Basel) (2010) 0.83
Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res (2014) 0.83
Tissue microarrays: applications in urological cancer research. World J Urol (2006) 0.82
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clin Investig (Lond) (2014) 0.82
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer. PLoS One (2015) 0.82
The development of a cell array and its combination with laser-scanning cytometry allows a high-throughput analysis of nuclear DNA content. Am J Pathol (2000) 0.81
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer (2007) 0.81
Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis. Oncol Lett (2015) 0.81
PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget (2015) 0.80
Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling. Int J Mol Sci (2013) 0.80
Microvessel density of malignant and benign hepatic lesions and MRI evaluation. World J Gastroenterol (2004) 0.80
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist (2016) 0.80
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res (2014) 0.79
Construction and validation of a bone marrow tissue microarray. J Clin Pathol (2006) 0.79
Activating mechanism of transcriptor NF-kappaB regulated by hepatitis B virus X protein in hepatocellular carcinoma. World J Gastroenterol (2004) 0.79
Numerical and structural genomic aberrations are reliably detectable in tissue microarrays of formalin-fixed paraffin-embedded tumor samples by fluorescence in-situ hybridization. PLoS One (2014) 0.79
Genetic and epigenetic changes in human prostate cancer. Iran Red Crescent Med J (2011) 0.79
Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva. Graefes Arch Clin Exp Ophthalmol (2005) 0.78
Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer (2014) 0.78
ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Arch (2012) 0.78
Targeting c-MYC with T-cells. PLoS One (2013) 0.78
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget (2015) 0.78
Androgen Receptor-dependent Expression of Low-density Lipoprotein Receptor-related Protein 6 is Necessary for Prostate Cancer Cell Proliferation. Korean J Physiol Pharmacol (2015) 0.78
ERK and JNK activation is essential for oncogenic transformation by v-Rel. Oncogene (2010) 0.77
Basic science of hormonal therapy for prostate cancer. Rev Urol (2001) 0.77
[Mucinous spindle cell carcinoma of the kidney. A molecular analysis]. Pathologe (2003) 0.77
Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Sci Rep (2016) 0.76
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res (2015) 0.76
A Mechanistic Beta-Binomial Probability Model for mRNA Sequencing Data. PLoS One (2016) 0.76
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol (2016) 0.76
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (1992) 16.38
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A (1994) 5.74
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet (2001) 3.99
Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res (1995) 3.98
Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int (2000) 3.86
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res (2000) 3.83
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst (2000) 3.12
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol (2001) 3.09
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst (2001) 2.93
Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol (2001) 2.91
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res (1999) 2.79
Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med (2000) 2.63
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer (2006) 2.45
Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol (1999) 2.25
Genome screening by comparative genomic hybridization. Trends Genet (1997) 2.23
High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol (1999) 2.22
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol (2001) 2.20
Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer (2001) 2.17
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A (2001) 2.16
Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res (2000) 2.13
Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer (1999) 2.05
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Karyomegalic interstitial nephritis: further support for a distinct entity and evidence for a genetic defect. Am J Kidney Dis (1995) 2.01
Quantitative studies of in situ immune complex glomerulonephritis in the rat induced by planted, cationized antigen. J Exp Med (1982) 2.00
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst (1992) 1.94
Health hazards posed by feral pigeons. J Infect (2004) 1.93
Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int (1999) 1.92
A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem (1999) 1.92
Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res (2000) 1.92
Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med (1992) 1.91
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 1.89
Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst (2000) 1.86